Egeberg, Alexander http://orcid.org/0000-0001-8257-1816
Hawkes, Jason E.
Somani, Najwa
Burge, Russel
See, Kyoungah
Gallo, Gaia
McKean-Matthews, Missy
Gooderham, Melinda
Han, George
Armstrong, April
Clinical trials referenced in this document:
Documents that mention this clinical trial
Sustained Improvements in Clinical and Patient-Reported Outcomes and Quality of Life Through 5 Years Among Ixekizumab-Treated Patients with Complete Clearance of Scalp Psoriasis by Week 60
https://doi.org/10.1007/s13555-024-01147-7
A Comprehensive Review of Ixekizumab Efficacy in Nail Psoriasis from Clinical Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis
https://doi.org/10.1007/s40744-023-00553-1
Simultaneous Nail and Skin Clearance in Ixekizumab Head-to-Head Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis
https://doi.org/10.1007/s13555-022-00704-2
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
https://doi.org/10.1016/s0140-6736(15)60125-8
Documents that mention this clinical trial
Sustained Improvements in Clinical and Patient-Reported Outcomes and Quality of Life Through 5 Years Among Ixekizumab-Treated Patients with Complete Clearance of Scalp Psoriasis by Week 60
https://doi.org/10.1007/s13555-024-01147-7
A Comprehensive Review of Ixekizumab Efficacy in Nail Psoriasis from Clinical Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis
https://doi.org/10.1007/s40744-023-00553-1
Simultaneous Nail and Skin Clearance in Ixekizumab Head-to-Head Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis
https://doi.org/10.1007/s13555-022-00704-2
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
https://doi.org/10.1016/s0140-6736(15)60125-8
Documents that mention this clinical trial
Sustained Improvements in Clinical and Patient-Reported Outcomes and Quality of Life Through 5 Years Among Ixekizumab-Treated Patients with Complete Clearance of Scalp Psoriasis by Week 60
https://doi.org/10.1007/s13555-024-01147-7
A Comprehensive Review of Ixekizumab Efficacy in Nail Psoriasis from Clinical Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis
https://doi.org/10.1007/s40744-023-00553-1
Simultaneous Nail and Skin Clearance in Ixekizumab Head-to-Head Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis
https://doi.org/10.1007/s13555-022-00704-2
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
https://doi.org/10.1016/s0140-6736(15)60125-8
Funding for this research was provided by:
Eli Lilly and Company
Article History
Received: 9 January 2024
Accepted: 20 March 2024
First Online: 22 April 2024
Declarations
:
: Alexander Egeberg is now an employee of LEO Pharma, has received research funding from Pfizer, Eli Lilly and Company, Novartis, Bristol-Myers Squibb, AbbVie, Janssen Pharmaceuticals, Boehringer Ingelheim, the Danish National Psoriasis Foundation, the Simon Spies Foundation, and the Kgl Hofbundtmager Aage Bang Foundation, and honoraria as consultant and/or speaker from AbbVie, Almirall, LEO Pharma, Zuellig Pharma Ltd., Galápagos NV, Sun Pharma, Samsung Bioepis Co., Ltd., Pfizer, Eli Lilly and Company, Novartis, Union Therapeutics, Galderma, Dermavant, UCB, Mylan, Bristol-Myers Squibb, McNeil Consumer Healthcare, Horizon Therapeutics, Boehringer Ingelheim, and Janssen Pharmaceuticals. Jason E. Hawkes currently serves on the medical board and scientific advisory committee of the National Psoriasis Foundation and as a consultant for AbbVie, Arcutis, Boehringer Ingelheim, Bristol-Myers Squibb, Janssen, LEO Pharma, Eli Lilly and Company, Novartis, Pfizer, Regeneron-Sanofi, Sun Pharma, and UCB. Najwa Somani, Russel Burge, Kyoungah See, and Gaia Gallo are employees and stockholders of Eli Lilly and Company. Missy McKean-Matthews reports working for Eli Lilly and Company through Syneos Health. Melinda Gooderham has received honoraria, grants, and/or research funding as a speaker, investigator, advisory board member, data safety monitoring board member, and/or consultant for AbbVie, Amgen, Arcutis, AnaptysBio, Aristea, Bausch Health, Boehringer Ingelheim, Celgene, Dermira, Dermavant, Eli Lilly and Company, Galderma, GlaxoSmithKline, Janssen, Kyowa Kirin, LEO Pharma, MedImmune, Merck Sharp & Dohme, Meiji, Moonlake, Nimbus, Novartis, Pfizer, Regeneron, Roche, Sanofi Genzyme, Sun Pharma, Takeda, Tarsus, UCB Pharma, and Ventyx. George Han is or has been an investigator, consultant/advisor, or speaker for AbbVie, Arcutis, Athenex, Boehringer Ingelheim, Bond Avillion, Bristol-Myers Squibb, Celgene Corporation, Dermavant, Eli Lilly and Company, Incyte, Janssen, LEO Pharma, MC2, Novartis, Ortho Dermatologics, PellePharm, Pfizer, Regeneron, Sanofi Genzyme, Sun Pharma, and UCB. April Armstrong has served as a research investigator and/or scientific advisor to AbbVie, Almirall, Arcutis, ASLAN, Beiersdorf, BI, Bristol-Myers Squibb, EPI, Incyte, LEO Pharma, UCB, Janssen, Eli Lilly and Company, Nimbus, Novartis, Ortho Dermatologics, Sun Pharma, Dermavant, Dermira, Sanofi, Regeneron, and Pfizer.
: The studies were conducted according to the principles of the Declaration of Helsinki and Council for International Organizations of Medical Sciences International Ethical Guidelines. An institutional review board reviewed and approved study protocols and informed consent forms at each participating site. All patients signed informed consent prior to undergoing study-related procedures.